MedTrace Logo

Effects of Different Early Intensive Therapies on Long-term β-cell Function

NCT01471808 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 264

Last updated 2025-09-24

No results posted yet for this study

Summary

The purpose of this study is to investigate and evaluate the effects of different oral antihyperglycaemic agents combined with short-term continuous subcutaneous insulin infusion(CSII)(1.CSII alone; 2.metformin and pioglitazone combined with CSII; 3. sitagliptin combined with CSII) on long-term glycemic control and β-cell function in newly diagnosed type 2 diabetic patients.

Conditions

  • Diabetes Mellitus, Type 2

Interventions

DRUG

CSII

continuous subcutaneous insulin infusion for 2\~4 weeks

DRUG

CSII, Metformin, Pioglitazone

CSII for 2\~4 weeks combined with metformin 1.5g/d and pioglitazone 30mg/d for 3 months.

DRUG

CSII, Sitagliptin

CSII for 2\~4 weeks combined with sitagliptin 100mg/d for 3 months

Sponsors & Collaborators

  • Nanfang Hospital, Southern Medical University

    collaborator OTHER

  • Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

    collaborator OTHER

  • Peking University Shenzhen Hospital

    collaborator OTHER

  • First People's Hospital of Foshan

    collaborator OTHER

  • Sun Yat-sen University

    lead OTHER

Principal Investigators

  • Yanbin Li, MD · Ministry of Education

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
25 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-10-31
Primary Completion
2018-12-31
Completion
2018-12-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01471808 on ClinicalTrials.gov